{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:11:18Z","timestamp":1791465078925,"version":"4.3.4"},"reference-count":80,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sci. Adv."],"published-print":{"date-parts":[[2022,4,29]]},"abstract":"<jats:p>Analysis of gene expression from cutaneous lupus erythematosus, psoriasis, atopic dermatitis, and systemic sclerosis using gene set variation analysis (GSVA) revealed that lesional samples from each condition had unique features, but all four diseases displayed common enrichment in multiple inflammatory signatures. These findings were confirmed by both classification and regression tree analysis and machine learning (ML) models. Nonlesional samples from each disease also differed from normal samples and each other by ML. Notably, the features used in classification of nonlesional disease were more distinct than their lesional counterparts, and GSVA confirmed unique features of nonlesional disease. These data show that lesional and nonlesional skin samples from inflammatory skin diseases have unique profiles of gene expression abnormalities, especially in nonlesional skin, and suggest a model in which disease-specific abnormalities in \u201cprelesional\u201d skin may permit environmental stimuli to trigger inflammatory responses leading to both the unique and shared manifestations of each disease.<\/jats:p>","DOI":"10.1126\/sciadv.abn4776","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T13:58:46Z","timestamp":1651240726000},"source":"Crossref","is-referenced-by-count":58,"title":["Machine learning reveals distinct gene signature profiles in lesional and nonlesional regions of inflammatory skin diseases"],"prefix":"10.1126","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5594-2618","authenticated-orcid":true,"given":"Brittany A.","family":"Mart\u00ednez","sequence":"first","affiliation":[{"name":"AMPEL BioSolutions, LLC and the RILITE Research Institute, Charlottesville, VA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8528-5313","authenticated-orcid":true,"given":"Sneha","family":"Shrotri","sequence":"additional","affiliation":[{"name":"AMPEL BioSolutions, LLC and the RILITE Research Institute, Charlottesville, VA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9923-4709","authenticated-orcid":true,"given":"Kathryn M.","family":"Kingsmore","sequence":"additional","affiliation":[{"name":"AMPEL BioSolutions, LLC and the RILITE Research Institute, Charlottesville, VA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7304-1987","authenticated-orcid":true,"given":"Prathyusha","family":"Bachali","sequence":"additional","affiliation":[{"name":"AMPEL BioSolutions, LLC and the RILITE Research Institute, Charlottesville, VA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7142-2284","authenticated-orcid":true,"given":"Amrie C.","family":"Grammer","sequence":"additional","affiliation":[{"name":"AMPEL BioSolutions, LLC and the RILITE Research Institute, Charlottesville, VA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9287-1676","authenticated-orcid":true,"given":"Peter E.","family":"Lipsky","sequence":"additional","affiliation":[{"name":"AMPEL BioSolutions, LLC and the RILITE Research Institute, Charlottesville, VA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/096120339700600204"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000739"},{"key":"e_1_3_3_4_2","first-page":"834291","article-title":"Cutaneous manifestations of systemic lupus erythematosus","volume":"2012","author":"Uva L.","year":"2012","unstructured":"L. Uva, D. Miguel, C. Pinheiro, J. P. Freitas, M. Marques Gomes, P. Filipe, Cutaneous manifestations of systemic lupus erythematosus. Autoimmune Dis. 2012, 834291 (2012).","journal-title":"Autoimmune Dis."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0272-0"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-017-8627-2"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316682097"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"e_1_3_3_10_2","first-page":"1061","article-title":"Biological therapies for atopic dermatitis: An update","volume":"17","author":"Deleanu D.","year":"2019","unstructured":"D. Deleanu, I. Nedelea, Biological therapies for atopic dermatitis: An update. Exp. Ther. Med. 17, 1061\u20131067 (2019).","journal-title":"Exp. Ther. Med."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.269"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0839-3"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801209"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI98219"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.40166"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800650"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.40052"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-019-0382-x"},{"key":"e_1_3_3_19_2","first-page":"1092","article-title":"Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways","volume":"159","author":"Nograles K. E.","year":"2008","unstructured":"K. E. Nograles, L. C. Zaba, E. Guttman-Yassky, J. Fuentes-Duculan, M. Su\u00e1rez-Fari\u00f1as, I. Cardinale, A. Khatcherian, J. Gonzalez, K. C. Pierson, T. R. White, C. Pensabene, I. Coats, I. Novitskaya, M. A. Lowes, J. G. Krueger, Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br. J. Dermatol. 159, 1092\u20131102 (2008).","journal-title":"Br. J. Dermatol."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14153"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.01.011"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93034-w"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009753"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.318"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041257"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800013"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140380"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20085"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19800"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.12.018"},{"key":"e_1_3_3_32_2","first-page":"1","article-title":"Immunopathogenic mechanisms in psoriasis","volume":"135","author":"Valdimarsson H.","year":"2004","unstructured":"H. Valdimarsson, J. E. Gudjonsson, A. Johnston, H. Sigmundsdottir, H. Valdimarsson, Immunopathogenic mechanisms in psoriasis. Clin. Exp. Immunol. 135, 1\u20138 (2004).","journal-title":"Clin. Exp. Immunol."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3066"},{"key":"e_1_3_3_34_2","first-page":"47","article-title":"IL-21R is essential for epicutaneous sensitization and allergic skin inflammation in humans and mice","volume":"119","author":"Jin H.","year":"2009","unstructured":"H. Jin, M. K. Oyoshi, Y. Le, T. Bianchi, S. Koduru, C. B. Mathias, L. Kumar, S. Le Bras, D. Young, M. Collins, M. J. Grusby, J. Wenzel, T. Bieber, M. Boes, L. E. Silberstein, H. C. Oettgen, R. S. Geha, IL-21R is essential for epicutaneous sensitization and allergic skin inflammation in humans and mice. J. Clin. Invest. 119, 47\u201360 (2009).","journal-title":"J. Clin. Invest."},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.3892\/br.2013.166"},{"key":"e_1_3_3_36_2","first-page":"585","article-title":"Smooth muscle differentiation in scleroderma fibroblastic cells","volume":"137","author":"Sappino A. P.","year":"1990","unstructured":"A. P. Sappino, I. Masouye, J. H. Saurat, G. Gabbiani, Smooth muscle differentiation in scleroderma fibroblastic cells. Am. J. Pathol. 137, 585\u2013591 (1990).","journal-title":"Am. J. Pathol."},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms140612222"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1159\/000018394"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1159\/000053720"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22699"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24658"},{"key":"e_1_3_3_42_2","first-page":"875","article-title":"Psoriasis: Association of interleukin-17 gene polymorphisms with severity and response to treatment (Review)","author":"Pu\u0219ca\u0219 A.","year":"2019","unstructured":"A. Pu\u0219ca\u0219, A. C\u0103tan\u0103, C. Pu\u0219ca\u0219, I. Roman, C. Vornicescu, M. \u0218omlea, R. Or\u0103san, Psoriasis: Association of interleukin-17 gene polymorphisms with severity and response to treatment (Review). Exp. Ther. Med. 875\u2013880 (2019).","journal-title":"Exp. Ther. Med."},{"key":"e_1_3_3_43_2","doi-asserted-by":"crossref","unstructured":"A. C. Allison Billi F. Ma O. Plazyo M. Gharaee-Kermani R. Wasikowski G. A. Hile X. Xing C. M. Yee S. M. Rizvi M. P. Maz F. Wen L. C. Tsoi M. Pellegrini R. L. Modlin J. E. Gudjonsson J. M. Kahlenberg A. C. Billi F. Ma O. Plazyo M. G.-Kermani R. Wasikowski G. A. Hile X. Xing C. M. Yee S. M. Rizvi M. P. Maz F. Wen L. C. Tsoi M. Pellegrini R. L. Modlin J. E. Gudjonsson J. M. Kahlenberg Non-lesional and lesional lupus skin share inflammatory phenotypes that drive activation of CD16 + dendritic cells. bioRxiv 2021.09.17.460124 [Preprint]. 20 September 2021. https:\/\/doi.org\/10.1101\/2021.09.17.460124.","DOI":"10.1101\/2021.09.17.460124"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0386-1"},{"key":"e_1_3_3_45_2","doi-asserted-by":"crossref","unstructured":"T. M. Li K. R. Veiga N. Schwartz Y. Chinenov D. J. Oliver J. Lora A. Jabbari Y. Liu W. D. Shipman M. J. Sandoval I. F. Sollohub W. G. Ambler M. Rashighi J. G. Krueger N. Anandasabapathy C. P. Blobel T. T. Lu Type I interferon modulates Langerhans cell ADAM17 to promote photosensitivity in lupus. bioRxiv 2021.08.18.456792 [Preprint]. 18 August 2021. https:\/\/doi.org\/10.1101\/2021.08.18.456792.","DOI":"10.1101\/2021.08.18.456792"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21031"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2009.04057.x"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221662"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8081244"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.039362"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.10.041"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319891243"},{"key":"e_1_3_3_53_2","unstructured":"A study to assess the safety and efficacy of secukinumab in alleviating symptoms of discoid lupus erythematosus. U.S. Natl. Libr. Med. Clin. Trials (2021)."},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.04.055"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67763-X"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67566-6"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.010"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15258"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1853096"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.11.022"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1177\/205873920601900125"},{"key":"e_1_3_3_62_2","first-page":"A1","article-title":"Targeted therapy using intradermal injection of etanercept for remission induction in discoid lupus erythematosus (TARGET-DLE): Results from a proof-of-concept phase II trial","volume":"6","author":"Yuzaiful M.","year":"2019","unstructured":"M. Yuzaiful, M. Yusof, M. Wittmann, C. Fernandez, D. Wilson, S. Edward, G. Abignano, A. Alase, P. Laws, M. Goodfield, P. Emery, E. Vita, Targeted therapy using intradermal injection of etanercept for remission induction in discoid lupus erythematosus (TARGET-DLE): Results from a proof-of-concept phase II trial. Lupus Sci. Med. 6, A1\u2013A227 (2019).","journal-title":"Lupus Sci. Med."},{"key":"e_1_3_3_63_2","unstructured":"Targeted therapy using intradermal injection of etanercept for remission induction in discoid lupus erythematosus ( TARGET-DLE ). U.S. Natl. Libr. Med. Clin. Trials (2019)."},{"key":"e_1_3_3_64_2","first-page":"86","article-title":"Ustekinumab for psoriasis and psoriatic arthritis","volume":"39","author":"Gottlieb A. B.","year":"2012","unstructured":"A. B. Gottlieb, A. M. Goldminz, Ustekinumab for psoriasis and psoriatic arthritis. J. Rheumatol. 39, 86\u201389 (2012).","journal-title":"J. Rheumatol."},{"key":"e_1_3_3_65_2","unstructured":"A study of ustekinumab in participants with active systemic lupus erythematosus (2021); https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03517722?term=ustekinumab&cond=lupus&draw=2&rank=3."},{"key":"e_1_3_3_66_2","unstructured":"Janssen Pharmaceuticals Janssen announces discontinuation of phase 3 LOTUS study evaluating ustekinumab in systemic lupus erythematosus (2020); www.jnj.com\/janssen-announces-discontinuation-of-phase-3-lotus-study-evaluating-ustekinumab-in-systemic-lupus-erythematosus."},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32167-6"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aap9527"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044274"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.06.012"},{"key":"e_1_3_3_71_2","first-page":"15","article-title":"Cytokine responses in nonlesional psoriatic skin as clinical predictor to anti-TNF agents","volume":"75","author":"Tsoi L. C.","year":"2021","unstructured":"L. C. Tsoi, M. T. Patrick, S. Shuai, M. K. Sarkar, S. Chi, B. Ruffino, A. C. Billi, X. Xing, R. Uppala, C. Zang, J. Fullmer, Z. He, E. Maverakis, N. N. Mehta, B. E. Perez White, S. Getsios, Y. Helfrich, J. J. Voorhees, J. M. Kahlenberg, S. Weidinger, J. E. Gudjonsson, Cytokine responses in nonlesional psoriatic skin as clinical predictor to anti-TNF agents. J. Allergy Clin. Immunol. 75, 15\u201318 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tig.2013.05.010"},{"key":"e_1_3_3_73_2","doi-asserted-by":"crossref","unstructured":"S. H\u00e4nzelmann R. Castelo J. Guinney GSVA: Gene set variation analysis for microarray and RNA-Seq data (2013); www.biomedcentral.com\/1471-2105\/14\/7http:\/\/www.bioconductor.org.Background.","DOI":"10.1186\/1471-2105-14-7"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-1578(10)60455-2"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-017-0009-0"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1747.2003.12611.x"},{"key":"e_1_3_3_78_2","unstructured":"L. Breiman J. H. Friedman R. A. Olshen C. J. Stone Classification and Regression Trees (Chapman & Hall\/CRC Taylor & Francis Group 1984)."},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010933404324"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-106"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btw313"}],"container-title":["Science Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.science.org\/doi\/pdf\/10.1126\/sciadv.abn4776","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T17:30:23Z","timestamp":1704821423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.science.org\/doi\/10.1126\/sciadv.abn4776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":80,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2022,4,29]]}},"alternative-id":["10.1126\/sciadv.abn4776"],"URL":"https:\/\/doi.org\/10.1126\/sciadv.abn4776","relation":{},"ISSN":["2375-2548"],"issn-type":[{"value":"2375-2548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]},"article-number":"eabn4776"}}